Science Advances: First confirmed: epigenetic drug EZH2 inhibitors, which treat bladder cancer by activating the immune system

Bladder Cancer (BCa) is one of the most common malignancies in the urinary system, mostly in the form of transitional epithelial cell carcinoma

If bladder cancer is diagnosed at an early stage, the possibility of treatment is still very high, and the patient's 5-year survival is 77%, but the recurrence rate after bladder cancer treatment is as high as 70%, so developing more effective anti-bladder cancer methods has become a top priority for medical workers

On October 5, 2022, researchers at Northwestern University published a research paper titled "Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma" in Science Advances

The study is the first to confirm that Tazemetostat, an epigenetic drug currently used to treat lymphoma and sarcoma, is able to suppress bladder cancer

Joshua J.

EZH2 is a histone methyltransferase that catalyzes the trimethylation modification of histone H3 lysine-27 (H3K27me3) through its SET domain, thereby maintaining a state

Tazestat was developed by epigenetic drug development company Epizyme

He Zesitta

EZH2 is usually overexpressed in most solid tumors and plays a cancer-promoting role by 'locking' the tumor in the growth state, so it has become one of

Therefore, the research team tried to inhibit the expression of EZH2 gene in a mouse model of bladder cancer, and the results showed that after inhibition of EZH2, the tumor in the mouse model of bladder cancer shrank significantly, and the tumor was filled with immune cells

Joshua J.

Original Source:

ANDREA PIUNTI， et al.